Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 7901670, 8 pages
https://doi.org/10.1155/2017/7901670
Research Article

Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study

1Department of Psychiatry, Brains Hospital of Hunan Province, Changsha, China
2Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, Changsha, China

Correspondence should be addressed to Huiyong Huang; moc.621@86yhgnauh and Xuejun Liu; moc.qq@709151707

Received 4 June 2017; Accepted 12 October 2017; Published 26 November 2017

Academic Editor: Nunziatina De Tommasi

Copyright © 2017 Ping Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Polimanti, A. Agrawal, and J. Gelernter, “Schizophrenia and substance use comorbidity: A genome-wide perspective,” Genome Medicine, vol. 9, no. 1, article no. 25, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. J. P. McEvoy, M. Byerly, R. M. Hamer et al., “Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial,” Journal of the American Medical Association, vol. 311, no. 19, pp. 1978–1986, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. G. J. Masilamoni, S. Uthayathas, G. Koenig, L. Leventhal, and S. M. Papa, “Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile,” Neuropharmacology, vol. 110, pp. 449–457, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Keith and J. M. Kane, “Partial compliance and patient consequences in schizophrenia: our patients can do better,” Journal of Clinical Psychiatry, vol. 64, no. 11, pp. 1308–1315, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. Q.-J. Bo, Z.-M. Wang, X.-B. Li, X. Ma, C.-Y. Wang, and J. de Leon, “Adjunctive metformin for antipsychotic-induced hyperprolactinemia: a systematic review,” Psychiatry Research, vol. 237, pp. 257–263, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. B. J. Kinon, J. A. Gilmore, H. Liu, and U. M. Halbreich, “Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone,” Psychoneuroendocrinology, vol. 28, no. 2, pp. 55–68, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. W. J. Inder and D. Castle, “Antipsychotic-induced hyperprolactinaemia,” Australian & New Zealand Journal of Psychiatry, vol. 45, no. 10, pp. 830–837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Rubio-Abadal, N. Del Cacho, G. Saenz-Navarrete et al., “How hyperprolactinemia affects sexual function in patients under antipsychotic treatment,” Journal of Clinical Psychopharmacology, vol. 36, no. 5, pp. 422–428, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kanasaki, A. Oride, T. Hara, T. Mijiddorj, U. Sukhbaatar, and S. Kyo, “Interactions between two different G protein-coupled receptors in reproductive hormone-producing cells: the role of PACAP and its receptor PAC1R,” International Journal of Molecular Sciences, vol. 17, no. 10, article no. 1635, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. Á. L. Montejo, C. Arango, M. Bernardo et al., “Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics,” Frontiers in Neuroendocrinology, vol. 45, pp. 25–34, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Iwata, S. Nakajima, F. Caravaggio et al., “Threshold of dopamine D2/3 receptor occupancy for hyperprolactinemia in older patients with schizophrenia,” Journal of Clinical Psychiatry, vol. 77, no. 12, pp. e1557–e1563, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. U. Lertxundi, S. Domingo-Echaburu, J. Peral, and M. Garcia, “Antipsychotic induced symptomatic hyperprolactinemia: are dopamine agonists safe?” Psychopharmacol Bull, vol. 44, no. 3, pp. 66–68, 2011. View at Google Scholar
  13. M. Fric and G. Laux, “Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine and quetiapine,” Psychiatrische Praxis, Supplement, vol. 30, no. 2, pp. S97–S101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Romijn, “Hyperprolactinemia and prolactinoma,” Handbook of Clinical Neurology, vol. 124, pp. 185–195, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Arduc, F. Gokay, S. Isik et al., “Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience,” Journal of Endocrinological Investigation, vol. 38, no. 4, pp. 447–453, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. H.-N. Yuan, C.-Y. Wang, C. W. Sze et al., “A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with Schizophrenia,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 264–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. H. W. Yoon, J. S. Lee, S. J. Park et al., “Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: A multicenter, open-label, prospective study,” Clinical Neuropharmacology, vol. 39, no. 6, pp. 288–294, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Wang, D.-D. Tian, B. Zheng et al., “Peony-glycyrrhiza decoction, an herbal preparation, inhibits clozapine metabolism via cytochrome p450s, but not flavin-containing monooxygenase in in vitro models,” Drug Metabolism and Disposition, vol. 43, no. 7, pp. 1147–1153, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Man, X.-B. Li, H.-H. Wang et al., “Peony-glycyrrhiza decoction for antipsychotic-related hyperprolactinemia in women with schizophrenia: a randomized controlled trial,” Journal of Clinical Psychopharmacology, vol. 36, no. 6, pp. 572–579, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. Kay, A. Fiszbein, and L. A. Opler, “The positive and negative syndrome scale (PANSS) for schizophrenia,” Schizophrenia Bulletin, vol. 13, no. 2, pp. 261–276, 1987. View at Publisher · View at Google Scholar · View at Scopus
  21. B. M. Biller, A. Luciano, P. G. Crosignani et al., “Guidelines for the diagnosis and treatment of hyperprolactinemia,” Journal of Reproductive Medicine, vol. 44, no. 2, pp. 1075–1084, 1999. View at Google Scholar
  22. C. China Pharmacopoeia, Pharmacopoeia of the People's Republic of China, vol. 1, Chinese Medical Science and Technology Press, 10th edition, 2010.
  23. N. Bliesener, H. Yokusoglu, B. B. Quednow, D. Klingmüller, and K.-U. Kühn, “Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report,” Pharmacopsychiatry, vol. 37, no. 4, pp. 189–191, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Voicu, A. Medvedovici, A. E. Ranetti, and F. Ş. Rǎdulescu, “Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences,” Expert Opinion on Drug Metabolism & Toxicology, vol. 9, no. 8, pp. 955–968, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. F.-M. Werner and R. Coveñas, “Safety of antipsychotic drugs: focus on therapeutic and adverse effects,” Expert Opinion on Drug Safety, vol. 13, no. 8, pp. 1031–1042, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Wang, H. K. Wong, L. Zhang et al., “Not only dopamine D 2 receptors involved in peony-glycyrrhiza decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 39, no. 2, pp. 332–338, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Wang, W. Wang, Y. Zhou et al., “Studies on the regulatory effect of peony-glycyrrhiza decoction on prolactin hyperactivity and underlying mechanism in hyperprolactinemia rat model,” Neuroscience Letters, vol. 606, pp. 60–65, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Sun, L. Li, X. Huang et al., “The central mechanism of risperidone-induced hyperprolactinemia,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 76, pp. 134–139, 2017. View at Publisher · View at Google Scholar
  29. Y. Cong, H. Zou, G. Qiao et al., “Bilateral mammary duct ectasia induced by sulpiride-associated hyperprolactinemia: A case report,” Oncology Letters, vol. 9, no. 5, pp. 2181–2184, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Peuskens, L. Pani, J. Detraux, and M. de Hert, “The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review,” CNS Drugs, vol. 28, no. 5, pp. 421–453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. C. X. Xu, W. Huang, X. H. Zhao, Z. T. Liang, and W. Deng, “Effect of various doses aripiprazole on hyperprolactinemia induced by amisulpride and risperidone,” Chinese Journal of Psychiatry, vol. 48, no. 5, pp. 297–302, 2015. View at Google Scholar
  32. J. N. Wu, L. Y. Wang, W. D. Liu, W. S. Du, and W. B. Liu, “Efficacy of 2. 5,10,15 mg aripiprazole in treating amisulpride and risperidone-induced hyperprolactinemia,” Chin J Biochem Pharm, vol. 1, pp. 114-115, 2016. View at Google Scholar
  33. L. Y. Feng, S. Q. Yan, S. Q. Wu, and L. J. Zhang, “Experimental study on the analgesia mechanism of Paeornia and Glycyrrhiza decoction,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 25, no. 1, pp. 23–25, 2002. View at Google Scholar
  34. H. N. Yuan, C. Y. Wang, X. J. Feng, R. M. Liu, and J. Z. Zhang, “Controlled study of shaoyao-gancao decoction and bromicripton in hyperprolactinemia,” J Clin Psychol Med, vol. 15, no. 6, pp. 337-338, 2005. View at Google Scholar
  35. P. Fitzgerald and T. G. Dinan, “Prolactin and dopamine: what is the connection?” Journal of Psychopharmacology, vol. 22, supplement 2, pp. 12–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Haddad and A. Wieck, “Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management,” Drugs, vol. 64, no. 20, pp. 2291–2314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. B.-H. Lee, S.-G. Kang, T.-W. Kim, H.-J. Lee, H.-K. Yoon, and Y.-M. Park, “Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients,” Psychiatry and Clinical Neurosciences, vol. 66, no. 1, pp. 69–73, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Andrade, “Low-dose amisulpride and elevation in serum prolactin,” Journal of Clinical Psychiatry, vol. 74, no. 6, pp. e558–e560, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. J. W. Lee, Y. M. Park, S. H. Lee, S. G. Kang, B. H. Lee, and E. Park, “Amisulpride-induced hyperprolactinemia:preliminary study,” Korean Journal of Psychosom Medicine, vol. 19, no. 1, pp. 41–47, 2011. View at Google Scholar